These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 21784820

  • 1. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.
    Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Donate-Correa J, Cazaña-Pérez V, García-Pérez J.
    Clin J Am Soc Nephrol; 2011 Sep; 6(9):2272-9. PubMed ID: 21784820
    [Abstract] [Full Text] [Related]

  • 2. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group.
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [Abstract] [Full Text] [Related]

  • 3. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.
    Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C.
    Am J Kidney Dis; 2012 Feb; 59(2):177-85. PubMed ID: 22137672
    [Abstract] [Full Text] [Related]

  • 4. Soluble CD14 levels, interleukin 6, and mortality among prevalent hemodialysis patients.
    Raj DS, Carrero JJ, Shah VO, Qureshi AR, Bárány P, Heimbürger O, Lindholm B, Ferguson J, Moseley PL, Stenvinkel P.
    Am J Kidney Dis; 2009 Dec; 54(6):1072-80. PubMed ID: 19733948
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis.
    Tzanno-Martins C, Biavo BM, Ferreira-Filho O, Ribeiro-Junior E, João-Luiz MV, Degaspari S, Scavone C, Kawamoto E.
    Int J Immunopathol Pharmacol; 2014 Dec; 27(1):25-35. PubMed ID: 24674676
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.
    De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D'Haese PC, Neven E.
    Kidney Int; 2013 Jun; 83(6):1109-17. PubMed ID: 23486515
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
    Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY, Lin PW, Liu JH, Liao PY, Huang CC.
    Ren Fail; 2006 Jun; 28(8):701-7. PubMed ID: 17162430
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA.
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.
    Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E.
    Am J Kidney Dis; 1999 Apr; 33(4):694-701. PubMed ID: 10196011
    [Abstract] [Full Text] [Related]

  • 19. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.
    Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P.
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):61-8. PubMed ID: 18057307
    [Abstract] [Full Text] [Related]

  • 20. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.
    Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P.
    Am Heart J; 2005 May; 149(5):820-5. PubMed ID: 15894962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.